- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01968733
Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia (SOLITAIRE-IV)
March 1, 2017 updated by: Melinta Therapeutics, Inc.
A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in the Treatment of Adult Patients With Community-Acquired Bacterial Pneumonia
This study will evaluate the safety and efficacy of an experimental antibiotic, solithromycin, in the treatment of adult patients with community-acquired pneumonia.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Community-acquired bacterial pneumonia (CABP) is an acute infection of the pulmonary parenchyma with symptoms such as fever or hypothermia, chills, rigors, chest pain, and/or dyspnea.
The widespread emergence of antibiotic resistant pathogens, including the macrolide-resistant Streptococcus pneumoniae, has resulted in a need for new and effective antibiotics that have activity against CABP pathogens.
Solithromycin is a fourth generation macrolide antibiotic with excellent activity against resistant S. pneumoniae and other key typical and atypical bacterial respiratory pathogens.
A completed Phase 2 study showed comparable efficacy to levofloxacin in adults with CABP.
Study Type
Interventional
Enrollment (Actual)
863
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cordoba, Argentina, X5000JRD
-
Salta, Argentina, 4400
-
-
Buenos Aires
-
Caba, Buenos Aires, Argentina, C1093AAS
-
Florencia Varela, Buenos Aires, Argentina, B1887FWB
-
Florencio Varela, Buenos Aires, Argentina, 1888
-
La Plata, Buenos Aires, Argentina, B1900AVG
-
La Plata, Buenos Aires, Argentina, 1900
-
Loma Hermosa, Buenos Aires, Argentina, B1657BHD
-
Mar del Plata, Buenos Aires, Argentina, B7600GNY
-
Vicente Lopez, Buenos Aires, Argentina, B1602DOH
-
-
Santa Fe
-
Rosario, Santa Fe, Argentina, S2000CVB
-
-
Tucuman
-
San Miguel de Tucuman, Tucuman, Argentina, T4000IFL
-
-
-
-
-
Kozloduy, Bulgaria, 3320
-
Montana, Bulgaria, 3400
-
Pernik, Bulgaria, 2300
-
Russe, Bulgaria, 7002
-
Samokov, Bulgaria, 2000
-
Sofia, Bulgaria, 1431
-
Sofia, Bulgaria, 1606
-
Vidin, Bulgaria, 3700
-
Vratsa, Bulgaria, 3000
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G2B7
-
-
British Columbia
-
Surrey, British Columbia, Canada, V3V 1Z2
-
Vancouver, British Columbia, Canada, V6Z 1Y6
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E0J9
-
-
Quebec
-
Chicoutimi, Quebec, Canada, G7H5H6
-
Greenfield Park, Quebec, Canada, J4V2H1
-
Montreal, Quebec, Canada, H2W 1T8
-
Sherbrooke, Quebec, Canada, JIH-5N4
-
-
-
-
-
Temuco, Chile, 4800997
-
-
RM
-
Providencia, RM, Chile, 7500710
-
-
V Region
-
Vina del Mar, V Region, Chile, 2540364
-
-
VII Region
-
Talca, VII Region, Chile, 3465584
-
-
-
-
Antioquia
-
Medellin, Antioquia, Colombia
-
-
Valle del Cauca
-
Cali, Valle del Cauca, Colombia
-
-
-
-
-
Batumi, Georgia, 6004
-
Rustavi, Georgia, 3700
-
Tbilisi, Georgia, 0101
-
Tbilisi, Georgia, 0112
-
Tbilisi, Georgia, 0144
-
Tbilisi, Georgia, 0159
-
Tbilisi, Georgia, 0160
-
Tbilisi, Georgia, 0186
-
-
-
-
-
Bochum, Germany, 44789
-
Bonn, Germany, 53105
-
Dresden, Germany, 01307
-
Greifswald, Germany, 17475
-
Hannover, Germany, 30625
-
Lubeck, Germany, 23538
-
Rostock, Germany, 18055
-
-
-
-
-
Guatemala, Guatemala, 01010
-
Guatemala, Guatemala, 01016
-
-
-
-
-
Budapest, Hungary, H-1097
-
Budapest, Hungary, H-1121
-
Budapest, Hungary, H-1125
-
Budapest, Hungary, H-1145
-
Budapest, Hungary, H-115
-
Debrecen, Hungary, H-1051
-
Gyor, Hungary, H-9024
-
Kaposvar, Hungary, H-7400
-
Nagykanizsa, Hungary, H-8800
-
Nyiregyhaza, Hungary, H-4412
-
Pecs, Hungary, H-7623
-
Szekesfehervar, Hungary, H-8000
-
Torokbalint, Hungary, H-2045
-
-
-
-
Gyenggi
-
Seoul, Gyenggi, Korea, Republic of, 135-710
-
Seoul, Gyenggi, Korea, Republic of, 138-736
-
Seoul, Gyenggi, Korea, Republic of, 156-707
-
Seoul, Gyenggi, Korea, Republic of, 158-710
-
-
Gyenggi-do
-
Anyang-si, Gyenggi-do, Korea, Republic of, 431-796
-
-
Gyeonggi
-
Seoul, Gyeonggi, Korea, Republic of, 136-705
-
Seoul, Gyeonggi, Korea, Republic of, 143-729
-
Seoul, Gyeonggi, Korea, Republic of, 150-950
-
-
Gyeonggi-do
-
Ansan-si, Gyeonggi-do, Korea, Republic of, 425-707
-
Goyang-si, Gyeonggi-do, Korea, Republic of, 410-719
-
Goyang-si, Gyeonggi-do, Korea, Republic of, 411-706
-
-
Jeollabuk-do
-
Jeonju-si, Jeollabuk-do, Korea, Republic of, 561-712
-
-
-
-
-
Balvi, Latvia, LV-4501
-
Daugavpils, Latvia, LV-5417
-
Liepaja, Latvia, LV-3414
-
Valmiera, Latvia, LV-4201
-
-
-
-
-
Melaka, Malaysia, 75400
-
-
Kedah
-
Alor Setar, Kedah, Malaysia, 05460
-
-
Kelantan
-
Kota Bharu, Kelantan, Malaysia, 15586
-
-
Kuala Lumpur
-
Cheras, Kuala Lumpur, Malaysia, 56000
-
Jalan Pahang, Kuala Lumpur, Malaysia, 50586
-
-
Penang
-
Georgetown, Penang, Malaysia, 10400
-
-
Pulau Pinang
-
George Town, Pulau Pinang, Malaysia, 10990
-
-
Sarawak
-
Miri, Sarawak, Malaysia, 98000
-
-
Selangor
-
Ampang, Selangor, Malaysia, 68000
-
Batu Caves, Selangor, Malaysia, 68100
-
Sungai Buloh, Selangor, Malaysia, 47000
-
-
-
-
-
Utrecht, Netherlands, 3584 CX
-
-
Limburg
-
Maastricht, Limburg, Netherlands, 6229 HX
-
-
Noord-Brabant
-
Breda, Noord-Brabant, Netherlands, 4818 CK
-
-
-
-
-
Ica, Peru
-
-
Callao
-
Bellavista, Callao, Peru, Callao
-
-
Lima
-
Cercado, Lima, Peru, Lima01
-
-
Lima 1
-
Cercado, Lima 1, Peru, Lima 1
-
-
Lima 18
-
Miraflores, Lima 18, Peru, Lima 18
-
-
Lima 29
-
San Juan de Miraflores, Lima 29, Peru, Lima 29
-
-
Lima 31
-
San Martin de Porres, Lima 31, Peru, Lima 31
-
-
Lima 32
-
San Miguel, Lima 32, Peru, Lima 32
-
-
Lima 33
-
Santiago de Surco, Lima 33, Peru, Lima 33
-
-
Lima 41
-
San Borja, Lima 41, Peru, Lima 41
-
-
Lima1
-
Cercado de Lima, Lima1, Peru, Lima1
-
-
Lima11
-
Jesus Maria, Lima11, Peru, Lima11
-
-
Loreto
-
Iquitos, Loreto, Peru
-
-
-
-
-
Cebu City, Philippines, 6000
-
Iloilo City, Philippines, 5000
-
Quezon City, Philippines, 1100
-
Quezon City, Philippines, 1109
-
-
Batangas
-
Lipa City, Batangas, Philippines, 4217
-
-
Metro Manila
-
EDSA Caloocan City, Metro Manila, Philippines, 1400
-
-
-
-
-
Chrzanow, Poland, 32-500
-
Krakow, Poland, 31-011
-
Krakow, Poland, 31-209
-
Lodz, Poland, 90-153
-
Poznan, Poland, 60-569
-
Warszawa, Poland, 01-138
-
Warszawa, Poland, 02-507
-
Wroclaw, Poland, 21-162
-
-
-
-
-
Bucuresti, Romania, 011461
-
Constanta, Romania, 900002
-
-
Bihor
-
Marghita, Bihor, Romania, 415300
-
-
Cluj
-
Cluj-Napoca, Cluj, Romania, 400371
-
-
Dolj
-
Craiova, Dolj, Romania, 200515
-
-
Judetual Suceava
-
Suceava, Judetual Suceava, Romania, 720284
-
-
Judetul Suceava
-
Suceava, Judetul Suceava, Romania, 720284
-
-
Prahova
-
Ploiesti, Prahova, Romania, 10097
-
-
Sector 1
-
Bucuresti, Sector 1, Romania, 010824
-
-
Sector 2
-
Bucuresti, Sector 2, Romania, 021105
-
Bucuresti, Sector 2, Romania, 021661
-
-
Sector 3
-
Bucuresti, Sector 3, Romania, 030303
-
-
Sector 5
-
Bucuresti, Sector 5, Romania, 050159
-
-
Timis
-
Timisoara, Timis, Romania, 300310
-
-
judet Ilfov
-
Bragadiru, judet Ilfov, Romania, 769764
-
-
-
-
-
Barnaul, Russian Federation, 656045
-
Chelyabinsk, Russian Federation, 454021
-
Moscow, Russian Federation, 119991
-
Moscow, Russian Federation, 123182
-
Moscow, Russian Federation, 127206
-
Novosibirsk, Russian Federation, 195271
-
Penza, Russian Federation, 440067
-
Saint-Petersburg, Russian Federation, 195030
-
Saint-Petersburg, Russian Federation, 198205
-
Smolensk, Russian Federation, 214019
-
St. Petersburg, Russian Federation, 194354
-
St. Petersburg, Russian Federation, 195271
-
Tomsk, Russian Federation, 634063
-
-
-
-
-
Belgrade, Serbia, 11000
-
Belgrade, Serbia, 11080
-
Kragujevac, Serbia, 34000
-
Nis, Serbia, 18000
-
Sremska Kamenica, Serbia, 21204
-
-
-
-
-
Kosice-Saca, Slovakia, 04015
-
Lucenec, Slovakia, 98401
-
Trebisov, Slovakia, 07501
-
-
-
-
-
Golnik, Slovenia, 4204
-
Ljubljana, Slovenia, 1000
-
Topolsica, Slovenia, 3326
-
-
-
-
Gauteng
-
Benoni, Gauteng, South Africa, 1501
-
Johannesburg, Gauteng, South Africa, 2113
-
Krugersdorp, Gauteng, South Africa, 1739
-
-
Kwazulu, Natal
-
Newcastle, Kwazulu, Natal, South Africa, 2940
-
-
Limpopo
-
Thabazimbi, Limpopo, South Africa, 0380
-
-
Mpumalanga
-
Middleburg, Mpumalanga, South Africa, 1055
-
-
Western Cape
-
Observatory, Western Cape, South Africa, 7925
-
-
-
-
-
Alicante, Spain, 03010
-
Barcelona, Spain, 08036
-
Barcelona, Spain, 08003
-
Barcelona, Spain, 08035
-
Barcelona, Spain, 08221
-
Granada, Spain, 18014
-
Madrid, Spain, 28040
-
Madrid, Spain, 28046
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
-
Mataro, Barcelona, Spain, 08304
-
-
Madrid
-
Torrejon de Ardoz, Madrid, Spain, 28850
-
-
-
-
-
Changhua Country, Taiwan, 500
-
Hualien, Taiwan, 970
-
Kaohsiung, Taiwan, 83301
-
Kaohsiung, Taiwan, 807
-
Kaohsiung City, Taiwan, 82445
-
New Taipei City, Taiwan, 220
-
Taichung, Taiwan, 40705
-
Taichung, Taiwan, 402
-
Tainan, Taiwan, 704
-
Tainan City, Taiwan, 710
-
Taipei, Taiwan, 100
-
Taipei, Taiwan, 114
-
Taipei City, Taiwan, 11217
-
-
R.o. C.
-
Taichung, R.o. C., Taiwan, 40447
-
Taichung, R.o. C., Taiwan, 407
-
Taipei City, R.o. C., Taiwan, 116
-
-
-
-
-
Chernivtsi, Ukraine, 58000
-
Ivano Frakivsk, Ukraine, 76018
-
Kharkiv, Ukraine, 61103
-
Kharkiv, Ukraine, 61106
-
Kharkiv, Ukraine, 61124
-
Kherson, Ukraine, 73000
-
Kiev, Ukraine, 01133
-
Kremenchuk, Ukraine, 39617
-
Sumy, Ukraine, 40022
-
Vinnytsia, Ukraine, 21029
-
Zaporizhzhia, Ukraine, 69035
-
Zaporizhzhia, Ukraine, 69065
-
-
-
-
Alabama
-
Mobile, Alabama, United States, 36607
-
Mobile, Alabama, United States, 36609
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
-
-
California
-
Chino, California, United States, 91710
-
Glendale, California, United States, 91206
-
Laguna Hills, California, United States, 92653
-
Los Angeles, California, United States, 90015
-
Pasadena, California, United States, 91105
-
Sacramento, California, United States, 95817
-
Sylmar, California, United States, 91342
-
Torrance, California, United States, 90502
-
-
Delaware
-
Newark, Delaware, United States, 19713
-
-
Florida
-
Bay Pines, Florida, United States, 33744
-
DeLand, Florida, United States, 32720
-
Doral, Florida, United States, 33166
-
Kissimmee, Florida, United States, 34741
-
Miami, Florida, United States, 33144
-
Miami, Florida, United States, 33156
-
West Palm Beach, Florida, United States, 33401
-
-
Georgia
-
Augusta, Georgia, United States, 30912
-
Blue Ridge, Georgia, United States, 30513
-
Decatur, Georgia, United States, 30033
-
-
Illinois
-
Chicago, Illinois, United States, 60611
-
Springfield, Illinois, United States, 62702
-
-
Iowa
-
Council Bluffs, Iowa, United States, 51503
-
-
Kentucky
-
Hazard, Kentucky, United States, 41701
-
Louisville, Kentucky, United States, 40202
-
Louisville, Kentucky, United States, 40206
-
Owensboro, Kentucky, United States, 42303
-
-
Louisiana
-
Lafayette, Louisiana, United States, 70503
-
Shreveport, Louisiana, United States, 71103
-
-
Michigan
-
Detroit, Michigan, United States, 48202
-
Farmington Hills, Michigan, United States, 48334
-
Royal Oak, Michigan, United States, 48073
-
-
Minnesota
-
Duluth, Minnesota, United States, 55805
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
-
-
Montana
-
Butte, Montana, United States, 59701
-
-
New Jersey
-
Newark, New Jersey, United States, 07102
-
Somers Point, New Jersey, United States, 08244
-
-
New York
-
Buffalo, New York, United States, 14215
-
Jamaica, New York, United States, 11418
-
Johnson City, New York, United States, 13790
-
New York, New York, United States, 10003
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27103
-
-
Ohio
-
Akron, Ohio, United States, 44304
-
Cincinnati, Ohio, United States, 45267
-
Cleveland, Ohio, United States, 44106
-
Columbus, Ohio, United States, 43210
-
Dayton, Ohio, United States, 45402
-
Lima, Ohio, United States, 45801
-
-
Pennsylvania
-
Bethleham, Pennsylvania, United States, 18015
-
Philadelphia, Pennsylvania, United States, 19141
-
Wyomissing, Pennsylvania, United States, 19610
-
-
South Dakota
-
Rapid City, South Dakota, United States, 57702
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
-
-
Texas
-
Houston, Texas, United States, 77030
-
Houston, Texas, United States, 77024
-
Houston, Texas, United States, 77011
-
Houston, Texas, United States, 77093
-
Splendora, Texas, United States, 77372
-
-
Virginia
-
Charlottesville, Virginia, United States, 22905-2877
-
-
Washington
-
Spokane, Washington, United States, 99202
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female patients ≥ 18 years of age
An acute onset of at least 3 of the following signs and symptoms (new or worsening):
- Cough
- Production of purulent sputum
- Shortness of breath (dyspnea)
- Chest pain due to pneumonia
At least 1 of the following:
- Fever
- Hypothermia
- Presence of pulmonary rales and/or evidence of pulmonary consolidation
- PORT Risk Class II, III, or IV
- Presence of lobar, multilobar, or patchy parenchymal infiltrate(s) consistent with acute bacterial pneumonia on a pulmonary imaging study
- Not received any systemic antibiotics during the prior 7 days
Exclusion Criteria:
- Ventilator-associated pneumonia
- Known anatomical or pathological bronchial obstruction or a history of bronchiectasis or documented severe chronic obstructive pulmonary disease
- Hospitalization within 90 days or residence in a long-term care facility within 30 days prior to the onset of symptoms
- Fungal pneumonia
- Pneumocystis jiroveci pneumonia
- Aspiration pneumonia
- Other non-infectious causes of pulmonary infiltrates
- Primary or metastatic lung cancer
- Cystic fibrosis
- Active or suspected tuberculosis
- HIV or myasthenia gravis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Moxifloxacin
Intravenous with the potential step-down to oral moxifloxacin
|
Other Names:
|
Experimental: Solithromycin
Intravenous with potential step-down to oral solithromycin
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Early clinical response rate in the Intent to Treat (ITT) population.
Time Frame: 72 [±12] hours after the first dose of study drug
|
To determine noninferiority (NI) in early clinical response rate, in at least 2 of the following 4 cardinal symptoms: cough, shortness of breath, chest pain, and sputum production
|
72 [±12] hours after the first dose of study drug
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Early clinical response rate in the microITT population
Time Frame: 72 [±12] hours after the first dose of study drug
|
To determine NI in early clinical response rate of intravenous to oral solithromycin compared to intravenous to oral moxifloxacin in the mITT population
|
72 [±12] hours after the first dose of study drug
|
Clinical success rates in the ITT and Clinically Evaluable (CE) populations
Time Frame: 5 to 10 days after the last dose of study drug
|
To determine the overall clinical success rates of intravenous to oral solithromycin compared to moxifloxacin
|
5 to 10 days after the last dose of study drug
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Brian D Jamieson, MD, Melinta Therapeutics, Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2013
Primary Completion (Actual)
July 1, 2015
Study Completion (Actual)
September 1, 2015
Study Registration Dates
First Submitted
October 21, 2013
First Submitted That Met QC Criteria
October 23, 2013
First Posted (Estimate)
October 24, 2013
Study Record Updates
Last Update Posted (Actual)
March 3, 2017
Last Update Submitted That Met QC Criteria
March 1, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Pneumonia
- Pneumonia, Bacterial
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Anti-Bacterial Agents
- Moxifloxacin
- Solithromycin
Other Study ID Numbers
- CE01-301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Community-acquired Bacterial Pneumonia
-
PfizerCompletedPneumonia, Pneumococcal | Gram-positive Bacterial Infections | Community Acquired InfectionsUnited States, Slovakia, Spain, Taiwan
-
Zai Lab (Hong Kong), Ltd.RecruitingCommunity-acquired Bacterial PneumoniaUnited States
-
Melinta Therapeutics, Inc.Biomedical Advanced Research and Development AuthorityTerminatedCommunity-acquired Bacterial PneumoniaSpain, United States, Philippines, Hungary, United Kingdom, Bulgaria
-
Melinta Therapeutics, Inc.CompletedCommunity-Acquired Bacterial PneumoniaUnited States, Canada
-
Albany Medical CollegeForest Laboratories; Albany College of Pharmacy and Health SciencesCompletedCommunity Acquired Bacterial PneumoniaUnited States
-
Clarametyx Biosciences, Inc.RecruitingCommunity-acquired Pneumonia | Bacterial PneumoniaUnited States
-
Paratek Pharmaceuticals IncCompletedCommunity-acquired PneumoniaUnited States
-
Paratek Pharmaceuticals IncActive, not recruitingCommunity-acquired Pneumonia | Bacterial PneumoniaBulgaria, Croatia, Georgia, Hungary, Poland, Russian Federation, Serbia, Ukraine
-
Durata Therapeutics Inc., an affiliate of Allergan...WithdrawnCommunity Acquired PneumoniaUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownCommunity Acquired PneumoniaChina
Clinical Trials on Solithromycin
-
Melinta Therapeutics, Inc.CompletedUncomplicated Urogenital GonorrheaUnited States
-
Melinta Therapeutics, Inc.Department of Health and Human ServicesCompletedBacterial InfectionUnited States, Bulgaria
-
Melinta Therapeutics, Inc.CompletedNonalcoholic SteatohepatitisUnited States
-
Melinta Therapeutics, Inc.National Institute of Allergy and Infectious Diseases (NIAID)CompletedUncomplicated Urogenital GonorrheaUnited States, Australia
-
National Institute of Allergy and Infectious Diseases...Completed
-
Melinta Therapeutics, Inc.Department of Health and Human ServicesCompletedBacterial InfectionsUnited States
-
Imperial College LondonMelinta Therapeutics, Inc.TerminatedPulmonary Disease, Chronic ObstructiveUnited Kingdom
-
Melinta Therapeutics, Inc.CompletedCommunity-acquired Bacterial PneumoniaSpain, United States, Hungary, Canada, Estonia, Russian Federation, Argentina, Bulgaria, Czech Republic, Dominican Republic, Ecuador, Germany, Latvia, Poland, Puerto Rico, Romania, South Africa
-
Melinta Therapeutics, Inc.CompletedCommunity-Acquired Bacterial PneumoniaUnited States, Canada
-
Melinta Therapeutics, Inc.Biomedical Advanced Research and Development AuthorityTerminatedCommunity-acquired Bacterial PneumoniaSpain, United States, Philippines, Hungary, United Kingdom, Bulgaria